BioCardia, Inc. Common Stock

BCDANASDAQ • USD
ThemeBiotech - Drug Development›Clinical-Stage Platforms
1.20 USD
↗ 0.11 (10.09%)AT CLOSE (11:59 AM EDT)
1.15
↘ 0.05 (4.58%)
POST MARKET (AS OF 07:57 PM EDT)
Post Market
AS OF 07:57 PM EDT
1.15
↘ 0.05 (4.58%)
🔴Market: CLOSED

BioCardia, Inc. Common Stock (BCDA) trades at $1.20 per share. The stock presents a mixed profile: our models indicate a Buy for technical indicators, while underlying fundamentals flash a Sell. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, exceptional Return on Equity (729.4%) and a bearish Death Cross on the long-term moving averages.

Technical & fundamental data as of Jun 26, 2026.

Open?$1.06
High?$1.24
Low?$1.05
Prev. Close?$1.09
Volume?1.5M
Avg. Volume?6.0M
VWAP?$1.17
Rel. Volume?0.25x
Bid / Ask
Bid?$0.98 × 100
Ask?$1.38 × 100
Spread?$0.40
Midpoint?$1.18
Valuation & Ratios
Market Cap?16.2M
Shares Out?11.4M
Float?7.9M
Float %?71.8%
P/E Ratio?N/A
P/B Ratio?-15.22
EPS?-$0.52
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
Themes
Biotech - Drug Development›Clinical-Stage PlatformsHealthcare - Genomics & Precision Medicine›Gene Therapy & Gene Editing
Employees
21
Market Cap
16.2M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.biocardia.com
Listed
1995-10-25
Address
320 SOQUEL WAY
SUNNYVALE, CA 94085
Phone: 650-226-0123
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
77
Short Sent.?
51
Piotroski F-Score?0/9Weak
Altman Z-Score?-152.23Distress
Confidence?41%Low
Full Fundamental Analysis →
Short InterestElevated
Short % of Float?5.58%Elevated
Short Interest?438.6K
Days to Cover?1.0
Free Float7.9M
Avg Daily Volume14.6M
Settlement Date2026-06-15
Financial Health
Current Ratio?0.41Weak
Quick Ratio?0.41Weak
Cash Ratio?0.34Low
Debt/Equity?-0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
S&P
97
-15.22CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-2.0CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
Peers
50
S&P
97
729.4%STRONG▾
ROA?
S&P
3
-454.2%WEAK▾
Cash Flow & Enterprise
FCF?$-7487000
Enterprise Value?$15.3M
Fundamentals ratios updated end of day
MarketsMoversWatchlist